Rheumatoid Arthritis
2 years ago
Joy et al. Disease activity rather than steroid use increases risk of diabetes in RA in BeST study over 10 years. @RheumNow #ACR22 Abstr#1987 https://t.co/VT2eb3Q4m9 https://t.co/kquZ70o9bU
2 years ago
Krijbolder et al. TREAT EARLIER DBRCT. MTX vs PBO for pre-RA. Treat 1 year, stop, and follow 1 year. No difference in RA development. Delay in ACPA+ or high risk. Sustained benefit in MTX group on pain, EMS, function, MRI. @RheumNow #ACR22 Abstr#1603 https://t.co/M2qQfgrhC1 https://t.co/UUeknTLx0K
2 years ago
Does curcurmin (tumeric) do anything in RA?
Big talk & sales.
Best chance would be keeping pts in remission during csDMARD taper:
DBRCT n=200
52w, high bioavail form, good serum conc
Absolutely nothing vs placebo
I'll call it: just doesn't work in RA
ABST1587 #ACR22 @RheumNow https://t.co/wecEfkXT55
2 years ago
Wipfler et al. 1 in 17 individuals prescibed MTX experienced an unexpected barrier in Post-Roe era. @RheumNow #ACR22 Abstr#L09 https://t.co/a8RDZF3JKy https://t.co/cyxJj2adgw
2 years ago
#ACR22 Abstr#1756 More data on safety of #COVID vaccine to cite when counselling patients with inflammatory arthritis (IA). Data from COVAX registry (over 7000 pts) showed rates of serious adverse event was low 0.3% vs 2.5% in those with non-IA RMD group
@RheumNow https://t.co/iucDK1GpU4
2 years ago
Deane et al STOP RA trial. DBRCT HCQ vs PBO pre-RA. Treat 1 year, stop, 2 year follow up. Does not prevent RA development. Literally no effect at all, even during treatment phase. @RheumNow #ACR22 Abstr#1604 https://t.co/7jHv7cs5DT https://t.co/GNblKs90RU
2 years ago
Charlton et al PsA patients face longer diagnostic delay and less intensive treatment than RA patients for equivalent disease activity. @RheumNow #ACR22 Abstr#1613 https://t.co/HedK59QsKs https://t.co/xaJUy7w1t4
2 years ago
Preventing #rheumatoid #arthritis - the holy grail! STOPRA RCT of strong ACPA+; CCP3 high titre. No inflammatory arthritis. RCT of #Hydroxychloroquine vs placebo, N=142 Pts. At 3 yrs NO DIFF in onset@of RA in each group. identical curves. Abst1604 #ACR22 #ACRBest @RheumNow Darn! https://t.co/bEgbkxGSR4
2 years ago
Abs 1417 finds physicians prefer ABA over TNFi for RF/ACPA+ pts w/ higher disease severity, older age, the presence of extra-articular manifestations, and comorbidities such as heart failure. My question: Trouble getting it first line? #ACR22 @RheumNow https://t.co/tlFMgjgDNM https://t.co/ukoeLgSSUd